Breaking News
July 15, 2018 - Parents who had severe trauma, stresses in childhood more likely to have kids with behavioral health problems
July 15, 2018 - At colloquium, a range of views on value of predictive algorithms | News Center
July 15, 2018 - Pittcon invites oral and poster presentations for 2019 Technical Program
July 15, 2018 - Virtual reality could offer psychotherapy for fear of heights, study shows
July 15, 2018 - Retooled vaccine raises hopes as a lower-cost treatment for Type 1 diabetes
July 15, 2018 - Kolon TissueGene To Start US Phase III Clinical Trial For Invossa
July 15, 2018 - Study finds prenatal marijuana use can affect infant size, behavior
July 15, 2018 - Howard Chang named HHMI investigator | News Center
July 15, 2018 - Study shows tailored mental health services improve wellbeing of emerging adults
July 15, 2018 - A bright future might help teens steer clear of violence
July 15, 2018 - Stanford Medicine magazine explores the art, science of listening and hearing | News Center
July 15, 2018 - New study tracks how the brain turns simple sensory inputs into meaningful categories
July 15, 2018 - Deadlier subtype of metastatic prostate cancer found to be common than previously thought
July 15, 2018 - UZH scientists identify enzyme that controls cell division
July 15, 2018 - Unhealthy Food Behaviors May Signal Eating Disorder in Teen
July 15, 2018 - Study raises doubts on a previous theory of Parkinson’s disease
July 15, 2018 - Grant awarded to study whether stem cells can treat urinary incontinence | News Center
July 15, 2018 - Imaging techniques may help assess immune system recovery in HIV patients
July 15, 2018 - Machine-learning may aid in diagnosis and treatment of mental health disorders
July 15, 2018 - ‘Skin Cancer, Take A Hike!’ program promotes sun safety and skin cancer awareness
July 15, 2018 - Blink Health announces lowest prices for generic prescriptions through Blue Eagle Health
July 15, 2018 - New drug strategy can alleviate multiple behavioral, cellular deficiencies in FXS mouse model
July 15, 2018 - Georgia State professor receives federal grant to study virus similar to Ebola virus
July 15, 2018 - Quitting Smoking? Even a Little Exercise Can Help You Stay Slim
July 15, 2018 - DBS treatment may slow the progression of Parkinson’s tremor in early-stage patients
July 15, 2018 - 5 Questions: Luby on virus with potential to cause global pandemic | News Center
July 15, 2018 - Corn loses its cancer-fighting phenolic acids when processed into cornflakes
July 15, 2018 - Study uncovers possible link between iron loading, alcohol intake and mortality
July 15, 2018 - Molecular insights of NagA enzyme could help combat TB
July 15, 2018 - The Facts on Tampons—and How to Use Them Safely
July 15, 2018 - Normalisation of ‘plus-size’ risks hidden danger of obesity, study finds
July 15, 2018 - $2.5 million award to support physician-scientist training | News Center
July 15, 2018 - Aeras announces publication of Phase 2 results of two TB vaccines
July 15, 2018 - Public to set research priorities in field of ethnic inequalities and severe mental illness
July 15, 2018 - Eisai and Biogen Announce Positive Topline Results of the Final Analysis for BAN2401 at 18 Months
July 15, 2018 - U.S. obesity rates rising again
July 15, 2018 - Millions could have incorrect statin, aspirin and blood pressure prescriptions | News Center
July 15, 2018 - Researchers identify factors associated with cell phone-related distracted driving in parents
July 15, 2018 - Bioethicists suggest ethical considerations for forensic use of genetic data
July 15, 2018 - Most clinical trial participants find benefits of sharing personal data outweigh risks, Stanford study finds | News Center
July 14, 2018 - Researchers solve protein puzzle that paves way for new cancer therapies
July 14, 2018 - Blood telomeres can help predict risk of disease worsening or death in COPD patients
July 14, 2018 - CDC: Nearly One-Third of Injury Deaths Occur at Home
July 14, 2018 - Injectable electronics offer powerful new tool in understanding how retinal cells work
July 14, 2018 - Human blood cells transformed into functional neurons | News Center
July 14, 2018 - Podcast: KHN’s ‘What the Health?’ ACA under fire. Again.
July 14, 2018 - Small device with motion sensors can predict older adults’ risk of falling
July 14, 2018 - Neurological Fallout From Ebola Infection Worse Than Thought
July 14, 2018 - Screening for impaired vision in older adults: New Canadian guideline
July 14, 2018 - Blood test for pregnant women can predict premature birth, Stanford-led study reports | News Center
July 14, 2018 - Study uncovers process that neutralizes tumor cells
July 14, 2018 - Four-protein biomarker blood test improves lung cancer risk assessment for smokers
July 14, 2018 - Researchers develop novel approach to bridge gap in cell-free systems
July 14, 2018 - Research reveals new gears in the circadian clock
July 14, 2018 - Researchers assess role of physician in preventing intimate partner violence perpetration
July 14, 2018 - Two diabetes medications don’t slow progression of type 2 diabetes in youth
July 14, 2018 - New clues to restoring fertility in women with disabling ovary disorder
July 14, 2018 - Compound in citrus oil could reduce dry mouth in head, neck cancer patients | News Center
July 14, 2018 - Streck ARM-D Kits detect more antibiotic resistance than comparable tests
July 14, 2018 - Study finds wide variations in follow-up imaging for women with non-metastatic breast cancer
July 14, 2018 - FDA expands its support for states to implement FSMA Produce Safety Rule
July 14, 2018 - CTI BioPharma Announces the Continuation without Modification of PAC203 Phase 2 Study of Pacritinib in Patients with Myelofibrosis Previously Treated with Ruxolitinib
July 14, 2018 - First-hand accounts of premature baby loss inspires new resource
July 14, 2018 - Study identifies cellular ‘death code’ | News Center
July 14, 2018 - Federal judge enters consent decree against Minnesota dairy farm for selling adulterated meat
July 14, 2018 - New web-based game motivates people to exercise more
July 14, 2018 - Calcium electrotransfer could be used to target cancer cells, study finds
July 14, 2018 - Researchers identify new region in mouse brain that affects appetite and body weight
July 14, 2018 - Repeated testing produces ‘practice effect’ that obscures true cognitive decline
July 14, 2018 - Amgen And UCB Resubmit Biologics License Application (BLA) For Evenity (romosozumab) To The US FDA
July 14, 2018 - New research detects brain cell that improves learning
July 14, 2018 - Spirit, Inspiring Change award winners announced | News Center
July 14, 2018 - Opioid patients face several barriers to treatment, study finds
July 14, 2018 - Black adults more likely to develop high blood pressure by age of 55
July 14, 2018 - Insurers fall short in catching and reporting Medicaid fraud, inspectors find
July 14, 2018 - Scientists identify structural and functional differences in human immune-surveillance protein
July 14, 2018 - FDA Approves TPOXX (tecovirimat) as the First Drug for the Treatment of Smallpox
July 14, 2018 - Visual perceptual skills are updated by process similar to memory reconsolidation, study finds
July 14, 2018 - Big Data in Precision Health focuses on how to make technology work for patient care | News Center
July 14, 2018 - New technique measures how well cancer drugs reach their targets
Scientists develop novel computational framework to support personalized cancer treatment

Scientists develop novel computational framework to support personalized cancer treatment

image_pdfDownload PDFimage_print

Researchers at Columbia University Irving Medical Center (CUIMC) have developed a highly innovative computational framework that can support personalized cancer treatment by matching individual tumors with the drugs or drug combinations that are most likely to kill them.

The study, published today on Nature Genetics, by Dr. Andrea Califano of Columbia University Irving Medical Center and Dr. Irvin Modlin of Yale University and Wren Laboratories LLC, co-senior author on the study, with collaborators from 17 research centers worldwide, details a proof of concept for a novel analytical platform applicable to any cancer type and validates its predictions on gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The latter represent a rare class of tumors of the digestive system that, when metastatic, are associated with poor survival.

In a comprehensive analysis of samples from 212 patients, the team first identified a new class of drug-targets, called master regulators, which are rarely if ever mutated in cancer patients, and then predicted the drugs that can specifically invert their activity. Surprisingly, even though tumors were analyzed on an individual patient basis, the algorithm predicted the same top drug – Entinostat – for almost half of the metastatic patients. More importantly, when tested in a xenograft transplant of the tumor in a mouse, this drug induced dramatic shrinking of the tumor, while drugs predicted to have partial or no effect were also validated to produce results in line with predictions. These data led to rapid IND (Investigational New Drug) approval by the FDA for a metastatic GEP-NET clinical trial that is open and recruiting patients at Columbia University.

The innovative approach proposed in this manuscript, OncoTreat, is now available as a New York State Department of Health approved test through the Department of Pathology and Cell Biology at CUIMC. The test was co-developed with DarwinHealth, a precision oncology company born out of the Califano Lab work. It is the only such test designed to predict drugs that are optimally matched to individual patient tumors for 10 different aggressive tumor subtypes of ovarian, breast, pancreas, prostate, bladder, and lung cancer, as well as meningioma, sarcoma, glioblastoma, and GEP-NETs.

“This manuscript represents a first proof of concept of what may become a valuable new tool to deliver an effective and systematic precision medicine approach to cancer patients that may complement what we are currently doing with genetic mutations,” says Dr. Califano, the Clyde and Helen Wu Professor of Chemical and Systems Biology and chair of the Department of Systems Biology at CUIMC.

“Using novel systems biology methodologies, which combine the use of supercomputers with large-scale pharmacological assays, we can computationally predict and prioritize drugs and drug combinations that will most effectively kill cancer cells,” explains Dr. Califano. “Such an approach is especially promising for patients with aggressive tumors, who lack actionable mutations, fail to respond to targeted inhibitors or immune-checkpoint inhibitors, or relapse following initial response to a standard of care drug or drug combination. These patients, who unfortunately represent the majority of the aggressive tumor cases, present few, if any, effective therapeutic options. We hope that OncoTreat may offer the oncologist new alternatives when they run out of approved therapies, alternatives that are predicated on an increasingly mechanistic understanding of cancer cell regulation and response to drugs rather than on educated guesswork.”

Dr. Modlin, who had initially proposed the concept of addressing Neuroendocrine tumors using the innovative strategy developed by Dr. Califano, commented that the successful demonstration of the efficacy of a pre-treatment molecular identification strategy was a significant advance on previous practice where treatment agents were used based upon serendipitous selection rather than objective molecular evidence. This work combined with the use of molecular signature tools in blood to monitor real-time efficacy of therapy on disease are likely to change the face of therapeutic management in many diseases.

OncoTreat’s precision medicine approach

The OncoTreat framework centers on identifying and analyzing actionable proteins in cancer patients, independent of their genetic mutations. Called master regulators (MR), these proteins are organized into small regulatory modules – so-called tumor checkpoints – which are responsible for regulating and ensuring the stability of tumor cells. Master regulators and tumor checkpoints can be efficiently and systematically elucidated using the VIPER algorithm developed by the Califano Lab and published in an earlier Nature Genetics manuscript; critically, these analyses allow tracking their activity through metastatic progression, relapse, and development of drug resistance. These computational models were built based on mathematical concepts from information theory and Bayesian statistics and have been extensively validated over the past decade.

MR proteins represent a novel class of tumor vulnerabilities and potential therapeutic targets that are being increasingly adopted by pharmaceutical companies. Extensive research has demonstrated that shutting down the activity of these proteins is catastrophic for tumor cells, making it virtually impossible for them to survive and grow in their environment. In this study, drug compounds are prioritized based on their ability to revert the coordinated activity of 50 such master regulator proteins, as identified by the analysis of tumor samples. Predicted activity reversal was surveyed from an analysis of drug assays both in cell lines and in vivo, in PDX (Patient-Derived Xenografts) mice models.

“Master regulators–a new Achilles’ heel of cancer–represent the engine room of the cancer cell, where the effects of all tumorigenic mutations come together. What OncoTreat is able to do is attack this convergence point with a therapeutic intervention,” says collaborator Gary Schwartz, MD, division chief of hematology and oncology at CUIMC and associate director of the Herbert Irving Comprehensive Cancer Center. “By collapsing this tumor bottleneck, blocking this Achilles’ heel, the cancer can no longer survive. This method is so innovative, requiring a lot of mathematical modeling and understanding. It’s a whole new approach to cancer therapeutics, taking us in an entirely new direction.”

Califano and team validated the OncoTreat approach on a cohort of 212 gastroenteropancreatic neuroendocrine tumors, a deliberate choice since GEP-NETs are rare and poorly characterized, making them one of the more challenging tumors to research. Their analysis identified several MR proteins, including key immune function modulators, whose role as critical tumor dependencies was experimentally confirmed. The GEP-NET cells were screened against a library of 107 compounds, and found that the drug, Entinostat, proved to successfully invert the activity of the top 50 MR proteins in 42 percent of GEP-NET patients, providing the rationale for the follow up clinical trial.

“It is certainly our hope that this may provide a short cut to identify viable candidates for phase 2 trials in this and other malignancies,” says coauthor Edward Gelmann, MD, professor of medicine and of pathology and cell biology at CUIMC.

In addition to its potential therapeutic value, OncoTreat provides novel insight into the mechanisms and maintenance of GEP-NETs. In future work, Califano and collaborators intend to expand this approach to cover more than 80% of human malignancies and to develop clinical trials that will test the predictions in patients.

Source:

http://www.cumc.columbia.edu/

Tagged with:

About author

Related Articles